Bright Green Corporation (BGXX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bright Green Corporation (BGXX) trades at $0.04 with AI Score 52/100 (Grade B). Bright Green Corporation cultivates, manufactures, and sells cannabis and cannabis-related products for research and pharmaceutical applications, operating under federal and state laws. Market cap: $7.26M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BGXX: BGXX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BGXX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BGXX: the 7 perspectives are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Bright Green Corporation (BGXX) Healthcare & Pipeline Overview
Bright Green Corporation, established in 2019, focuses on the legal cultivation, manufacturing, and sale of cannabis and cannabis-related products for research and pharmaceutical use, positioning itself within the specialty and generic drug manufacturing segment of the healthcare sector, while navigating stringent regulatory requirements.
What Is the Investment Thesis for BGXX?
Bright Green Corporation presents a speculative investment opportunity within the emerging legal cannabis market. With a market capitalization of $7.26M and a negative P/E ratio of -0.52, the company's financial performance indicates significant challenges. A key value driver is the potential expansion of legal cannabis markets for research and pharmaceutical applications. Upcoming catalysts include potential changes in federal cannabis regulations and expansion of state-level legalization, which could increase demand for Bright Green's products. However, significant risks include the company's negative profit margin of -3269.7% and gross margin of -59.0%, indicating substantial operational inefficiencies. The company's beta of -0.25 suggests a low correlation with the overall market, but this may also reflect its early stage and limited trading history. Investors should carefully consider the regulatory risks, financial instability, and competitive pressures within the cannabis industry.
Based on FMP financials and quantitative analysis
BGXX Key Highlights
- Market Cap of $7.26M reflects the company's small size and early stage of development.
- Negative P/E ratio of -0.52 indicates that the company is currently not profitable.
- Profit Margin of -3269.7% highlights significant operational inefficiencies and high costs relative to revenue.
- Gross Margin of -59.0% suggests that the company's cost of goods sold exceeds its revenue, indicating potential pricing or production issues.
- Beta of -0.25 indicates a low correlation with the overall market, but may also reflect limited trading history.
Who Are BGXX's Competitors?
BGXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRRTF Crescita Therapeutics Inc. | $0.56 | +0.00% | $10.40M | 50 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BGXX's Key Strengths?
- Legal compliance in a highly regulated industry.
- Focus on research and pharmaceutical applications.
- Potential for developing proprietary cannabis strains.
What Are BGXX's Weaknesses?
- Negative profit and gross margins.
- Small market capitalization.
- Limited operating history.
What Could Drive BGXX Stock Higher?
- Potential changes in federal cannabis regulations could expand the market for Bright Green's products.
- Expansion of state-level legalization of cannabis for medical and research purposes.
- Development of new cannabis-based therapies and products.
- Partnerships with pharmaceutical companies to develop and commercialize cannabis medicines.
What Are the Key Risks for BGXX?
- Financial-distress signal — its Altman Z-Score of -5.36 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory risks associated with the evolving legal landscape of cannabis.
- Financial instability due to negative profit and gross margins.
- Competition from established cannabis companies.
- Risk of federal prohibition or increased regulation of cannabis.
- Limited operating history and small market capitalization.
What Are the Growth Opportunities for BGXX?
- Expansion into New Legal Markets: As more states legalize cannabis for medical and research purposes, Bright Green Corporation has the opportunity to expand its operations and distribution network. The legal cannabis market is projected to reach $50 billion by 2028, offering significant growth potential for companies that can navigate the regulatory landscape and establish a strong market presence. This expansion could involve establishing new cultivation facilities, partnerships with local distributors, and strategic acquisitions of existing cannabis businesses.
- Development of Proprietary Cannabis Strains: Investing in research and development to create unique cannabis strains with specific therapeutic properties can provide Bright Green Corporation with a competitive advantage. The market for specialized cannabis products is growing, with increasing demand for strains tailored to specific medical conditions. By developing proprietary strains, Bright Green can differentiate itself from competitors and capture a larger share of the market. This strategy requires significant investment in research and development, but could yield high returns in the long term.
- Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop cannabis-based drugs and therapies can provide Bright Green Corporation with access to new markets and distribution channels. The pharmaceutical industry is increasingly interested in the potential of cannabis-based medicines, and partnerships with established pharmaceutical companies can accelerate the development and commercialization of these products. This strategy requires building strong relationships with pharmaceutical companies and demonstrating the scientific validity of Bright Green's cannabis products.
- Export to International Markets: As more countries legalize cannabis for medical and research purposes, Bright Green Corporation has the opportunity to export its products to international markets. The global cannabis market is projected to reach $100 billion by 2030, offering significant growth potential for companies that can navigate the complex regulatory requirements of international trade. This expansion requires establishing partnerships with international distributors and complying with the import regulations of each country.
- Focus on Research and Development: By focusing on the research and development of cannabis-based products for specific medical conditions, Bright Green Corporation can establish itself as a leader in the scientific cannabis market. This includes conducting clinical trials, publishing research papers, and collaborating with academic institutions. This strategy requires significant investment in research and development, but could yield high returns in the long term by creating innovative and effective cannabis-based therapies.
What Opportunities Does BGXX Have?
- Expansion into new legal markets.
- Partnerships with pharmaceutical companies.
- Growth in demand for cannabis-based therapies.
What Threats Does BGXX Face?
- Changing regulatory landscape.
- Competition from established cannabis companies.
- Risk of federal prohibition.
What Are BGXX's Competitive Advantages?
- Legal Compliance: Adherence to federal and state laws provides a barrier to entry for companies that cannot meet regulatory standards.
- Focus on Research and Pharmaceutical Applications: Specialization in these areas differentiates Bright Green from companies focused on recreational cannabis.
- Potential for Proprietary Strains: Development of unique cannabis strains can create a competitive advantage.
What Does BGXX Do?
Bright Green Corporation, founded in 2019 and based in Fort Lauderdale, Florida, operates within the healthcare sector, specifically in the drug manufacturers - specialty & generic industry. The company focuses on the cultivation, manufacturing, and sale of cannabis and cannabis-related products. Bright Green aims to legally serve the research and pharmaceutical markets under both federal and state regulations. Its core business involves producing cannabis for research purposes, pharmaceutical applications, and potential export, adhering to strict legal standards. The company's foundation is rooted in the emerging legal cannabis market, seeking to provide a consistent and compliant supply for medical and scientific purposes. Bright Green Corporation's positioning is centered on legal compliance and quality control in a highly regulated industry. The company aims to differentiate itself through adherence to federal and state laws, focusing on research and pharmaceutical applications rather than recreational use. As of 2026, Bright Green continues to navigate the evolving legal landscape of cannabis, seeking opportunities for growth within the bounds of regulatory frameworks.
What Products and Services Does BGXX Offer?
- Cultivates cannabis plants in compliance with federal and state laws.
- Manufactures cannabis-related products for research purposes.
- Sells cannabis and cannabis-related products to pharmaceutical companies.
- Provides cannabis for scientific research and development.
- Exports cannabis products to legally authorized international markets.
- Develops proprietary cannabis strains for specific medical applications.
How Does BGXX Make Money?
- Cultivation and processing of cannabis under legal frameworks.
- Sales of cannabis products to research institutions and pharmaceutical companies.
- Revenue generation through export of cannabis to approved international markets.
What Industry Does BGXX Operate In?
Bright Green Corporation operates in the evolving cannabis industry, specifically targeting the pharmaceutical and research sectors. The market is characterized by increasing legalization trends at the state level and potential federal regulatory changes. Competitors include companies like AYRWF (Ayr Wellness Inc.), AYURF (Ayr Wellness Inc.), CLCFF (Columbia Care Inc.), CNFHF (TerrAscend Corp.), and CRRTF (Cresco Labs Inc.), which are also navigating the complex regulatory landscape. The industry is experiencing growth in demand for cannabis-based products for medical and scientific purposes, but faces challenges related to regulatory compliance, market access, and competition from both legal and illegal sources. Bright Green's success depends on its ability to navigate these challenges and establish a sustainable competitive advantage.
Who Are BGXX's Key Customers?
- Pharmaceutical companies seeking cannabis for drug development.
- Research institutions studying the effects of cannabis.
- International markets with legal cannabis frameworks for research and medical use.
Key Financial Metrics
Return on assets is -75.4%, showing how much profit it generates from its asset base. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
Bright Green Corporation (BGXX) Valuation Context
Valued at $7.26M, BGXX is classified as a micro-cap stock. Relative to its peer group, BGXX's quantitative score of 52/100 is below the peer average of 64/100.
Company Profile
Bright Green Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. The company is led by CEO Lynn Stockwell. BGXX has traded publicly since 2022.
F-Score 1/9Financial Health
Bright Green Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.36 places it in the distress zone, a signal of elevated financial risk.
BGXX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Legal compliance in a highly regulated industry.
- Focus on research and pharmaceutical applications.
- Potential for developing proprietary cannabis strains.
- Upcoming: Potential changes in federal cannabis regulations could expand the market for Bright Green's products.
Bear Case
- Negative profit and gross margins.
- Small market capitalization.
- Limited operating history.
- Potential: Regulatory risks associated with the evolving legal landscape of cannabis.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | $92,877 | -$949,450 | -$0.01 |
Based on FMP financials and quantitative analysis
BGXX Latest News
No recent news available for BGXX.
BGXX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BGXX.
Price Targets
Wall Street price target analysis for BGXX.
BGXX MoonshotScore
What does this score mean?
The MoonshotScore rates BGXX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lynn Stockwell
CEO
Lynn Stockwell serves as the CEO of Bright Green Corporation, managing a small team of five employees. Information regarding Lynn Stockwell's prior experience and educational background is not available in the provided data. Therefore, a comprehensive background profile cannot be constructed. Further research would be needed to ascertain her qualifications and previous roles.
Track Record: Due to the limited information available, Lynn Stockwell's track record at Bright Green Corporation cannot be fully assessed. There is no data provided regarding specific achievements, strategic decisions, or company milestones under her leadership. The company's financial performance, as indicated by its negative profit and gross margins, suggests significant challenges during her tenure.
BGXX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bright Green Corporation may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, financial resources, or regulatory compliance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. These companies may not be required to adhere to the same stringent reporting standards, potentially leading to information asymmetry and increased volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Uncertainty regarding the company's financial viability.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's compliance with relevant regulations.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company is legally registered and operating.
- Company has a functional website and contact information.
- Company is engaged in a legitimate business activity.
- Company has a management team in place.
- Company is taking steps to comply with relevant regulations.
Bright Green Corporation Healthcare Stock: Key Questions Answered
What does Bright Green Corporation do?
Bright Green Corporation cultivates, manufactures, and sells cannabis and cannabis-related products legally under federal and state laws. The company focuses on serving the research and pharmaceutical markets by providing a compliant supply of cannabis for scientific and medical purposes. Bright Green aims to differentiate itself through strict adherence to legal standards and a focus on quality control, positioning itself as a reliable source for cannabis in regulated industries. The company's business model centers on cultivation, processing, and distribution of cannabis products to research institutions, pharmaceutical companies, and potentially international markets with legal cannabis frameworks.
What do analysts say about BGXX stock?
As of March 18, 2026, there is no available analyst coverage or consensus on Bright Green Corporation (BGXX) stock. Given the company's small market capitalization of $7.26M, negative P/E ratio, and challenging financial metrics, the stock is likely not widely followed by analysts. Investors should conduct their own thorough due diligence and consider the company's financial risks, regulatory environment, and competitive landscape before making any investment decisions. The absence of analyst coverage underscores the speculative nature of this investment.
What are the main risks for BGXX?
Bright Green Corporation faces several significant risks. Regulatory risks are paramount, as the legal status of cannabis remains uncertain at the federal level, and changes in state laws could impact the company's operations. Financial risks include the company's negative profit and gross margins, indicating potential solvency issues. Competition from larger, more established cannabis companies poses a threat to Bright Green's market share. Additionally, the company's small market capitalization and limited operating history increase the risk of volatility and illiquidity. Investors should carefully consider these risks before investing in BGXX.
What are the key factors to evaluate for BGXX?
Bright Green Corporation (BGXX) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does BGXX data refresh on this page?
BGXX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BGXX's recent stock price performance?
Bright Green Corporation (BGXX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Legal compliance in a highly regulated industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BGXX overvalued or undervalued right now?
Valuing Bright Green Corporation (BGXX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BGXX?
Before investing in Bright Green Corporation (BGXX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market stocks are inherently more risky than exchange-listed stocks.
- Financial data is limited and may not be fully representative of the company's performance.